Dergiler / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 4

The Ratios of Estradiol and Progesterone to Testosterone Influence the Severity of Facioscapulohumeral Muscular Dystrophy

Sayfa
190–196
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Given that both estrogen and testosterone treatment are considered in therapy, our results suggest that estrogen and progesterone but not testosterone are likely to be more effective on the severity of FSHD.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Facioscapulohumeral muscular dystrophy (FSHD) occurs as a consequence of genetic deletion of D4Z4 repeats on chromosome 4q35.
📊
Temel Bulgular & Veri:Aims: To evaluate the possible correlation between the severity of FSHD with sex hormones, age, and genetic deletion on chromosome 4q35.
💡
Sonuç & Katkı:Given that both estrogen and testosterone treatment are considered in therapy, our results suggest that estrogen and progesterone but not testosterone are likely to be more effective on the severity of FSHD.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: Facioscapulohumeral muscular dystrophy (FSHD) occurs as a consequence of genetic deletion of D4Z4 repeats on chromosome 4q35. Onset of FSHD is earlier in males, suggesting that testosterone may trigger the disease. In accordance, the rapid progression of disease in women after menopause suggests a protective role for estrogen and progesterone. No studies have examined levels of all these hormones in relation with the severity of FSHD. Aims: To evaluate the possible correlation between the severity of FSHD with sex hormones, age, and genetic deletion on chromosome 4q35. Subjects and Methods: D4Z4 repeat units were investigated in 33 patients (19 males/14 females) with FSHD. In the blood samples, luteinizing hormone, follicle-stimulating hormone, free estriol, estradiol, free testosterone and total testosterone, progesterone, 17-OH progesterone, prolactin, albumin, and fibrinogen were measured. The severity of FSHD was identified using a Clinical Severity Score (CSS) scaling system. Spearman’s correlation and regression analyses were performed as statistical analyses. Results: Age (P = 0.001, r = 0.541) and total testosterone (P = 0.045, r = 0.351) were positively correlated, and the progesterone/total testosterone (P = 0.025, r = −0.390) and estradiol/total testosterone ratios (P = 0.025, r = −0.389) were negatively correlated with the severity of FSHD. Conclusions: Our results indicate that age, total testosterone, ratios of estradiol and progesterone to total testosterone, but not deletion on chromosome 4q35, have a significant relation with the severity of FSHD. Given that both estrogen and testosterone treatment are considered in therapy, our results suggest that estrogen and progesterone but not testosterone are likely to be more effective on the severity of FSHD.

🔖

Bu Makaleye Atıf Yap

HANGÜL, C., BOZKURT, S., BİLGE, U., ÖZDEM, S., ALTUNBAŞ, H. A., UYSAL, H., KOÇ, A. F., KARAÜZÜM, S. B. (2020). The Ratios of Estradiol and Progesterone to Testosterone Influence the Severity of Facioscapulohumeral Muscular Dystrophy. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 4, 190–196. https://ajindex.com/articles/290593

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Statland J, Tawil R. Facioscapulohumeral muscular dystrophy. Neurol Clin 2014;32:721-8, ix
  2. Hewitt JE, Lyle R, Clark LN, Valleley EM, Wright TJ, Wijmenga C, et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 1994;3:1287-95. 3. de Greef JC, Lemmers RJ, van Engelen BG, Sacconi S, Venance SL, Frants RR, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 2009;30:1449-59
  3. Yamanaka G, Goto K, Ishihara T, Oya Y, Miyajima T, Hoshika A, et al. FSHD-like patients without 4q35 deletion. J Neurol Sci 2004;219:89-93
  4. Hamanaka K, Sikrova D, Mitsuhashi S, Masuda H, Sekiguchi Y, Sugiyama A, et al. Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology. 2020;94:e2441-7
  5. Pandya S, King WM, Tawil R. Facioscapulohumeral dystrophy. Phys Ther 2008;88:105-13
  6. Fitzsimons RB. Retinal vascular disease and the pathogenesis of facioscapulohumeral muscular dystrophy. A signalling message from Wnt? Neuromuscul Disord 2011;21:263-71
  7. Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC, Passos-Bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet 1998;77:155-61
  8. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004;14:33-8
  9. Puma A, Garibaldi M, Teveroni E, Deidda G, Moretti FS. Estrogens as a Potential Disease Modifier in FSHD: A Retrospective Clinical Study; 2017
  10. Mul K, Horlings CG, Voermans NC, Schreuder TH, van Engelen BG. Lifetime endogenous estrogen exposure and disease severity in female patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2018;28:508-11
  11. Teveroni E, Pellegrino M, Sacconi S, Calandra P, Cascino I, Farioli-Vecchioli S, et al. Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. J Clin Invest 2017;127:1531-45
  12. Banerji CR, Panamarova M, Pruller J, Figeac N, Hebaishi H, Fidanis E, et al. Dynamic transcriptomic analysis reveals suppression of PGC1 alpha/ERR alpha drives perturbed myogenesis in facioscapulohumeral muscular dystrophy. Human Molecular Genetics 2019;28:1244-59
  13. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Pr